KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to 0.05.

  • Alnylam Pharmaceuticals' Equity Ratio rose 52657.14% to 0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05, marking a year-over-year increase of 52657.14%. This contributed to the annual value of 0.02 for FY2024, which is 12746.46% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Equity Ratio stood at 0.05, which was up 52657.14% from 0.05 recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Equity Ratio high stood at 0.28 for Q1 2021, and its period low was 0.12 during Q2 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Equity Ratio value was 0.02 (recorded in 2024), while the average stood at 0.04.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Equity Ratio crashed by 32693.53% in 2023, and later soared by 727494.72% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Equity Ratio stood at 0.16 in 2021, then crashed by 127.63% to 0.04 in 2022, then decreased by 29.13% to 0.06 in 2023, then surged by 127.46% to 0.02 in 2024, then soared by 204.68% to 0.05 in 2025.
  • Its last three reported values are 0.05 in Q3 2025, 0.05 for Q2 2025, and 0.03 during Q1 2025.